4696 W. Overland Road, Suite 234
Boise, Idaho 83705

Newsroom

If you want to be in the know about what’s going on at our organization, you’ve come to the right place!


There are plenty of ways to cheer up somebody you love, many of them only involving your time.

86 percent of registered voters believe the government should require copay assistance to be applied to patients’ cost-sharing requirements 

Thirty three organizations, including NHF, urge elected officals to ensure all people living in the US have access to adequate and affordable health coverage.

The purpose of the study is to evaluate the efficacy and safety of this investigational gene therapy in patients with moderately severe to severe hemophilia A.

It’s never too early to start teaching your children about the impact they can have in the world by spreading kindness.

NHF’s Red Tie Soiree is a Virtual Success

On September 25, more than 300 people from across the country tuned in to this year’s virtual Red Tie Soiree.

Gene Therapy: What's New & What's Next Webinar

Watch this moderated webinar regarding the current status of gene therapies in the pipeline and other novel therapies.

Whether it be adopting an animal or helping in various other ways, we hope you’ll take part in Adopt a Shelter Dog Month.

HHS Announces New Coronavirus Funding for Healthcare Providers

The funding considers financial losses caused by the pandemic.

Primary care physicians, obstetrician/gynecologists, nurse/nurse practitioners, dentists, oral surgeons and other allied professionals are all encouraged to take advantage of these online activities.

CSL Behring States Stimate Will Not Be Resupplied until 2022

CSL Behring provided a statement to NHF nand HFA regarding the recall of Stimate® (desmopressin) nasal spray.

What's Next for the ACA?

How will the Trump administration's lawsuit against the ACA affect the bleeding disorders community?

The abstracts featured at this summer's BDC covered a wide spectrum of research topics.

Before you totally ‘write off’ the idea, consider the benefits that come along with journaling a little every day. Check out these five ways that getting your thoughts down on paper (or on your laptop) can help cultivate a more philanthropic focus.

This commentary was authored by six individuals with severe hemophilia, all of whom have worked to achieve better health outcomes for patients with bleeding disorders.

Unanswered Questions Remain for Gene Therapy

This commentary was authored by six individuals with severe hemophilia, all of whom have worked to achieve better health outcomes for patients with bleeding disorders.

With changing seasons comes more than just pumpkin-spice-flavored everything and crunchy fall leaves. The new season also brings forward new opportunities to do good out in the world.

Sanofi Publishes Updates to BIVV001 Trial

BIVV001 is a novel, investigational recombinant factor VIII therapy developed for the prevention of bleeding episodes in hemophilia A patients via once weekly prophylactic infusions.

NHF is Charting a Course for the Future

Your input will ensure that NHF is meeting your needs.

Mononine ® was first introduced as treatment available to hemophilia B patients in 1992.

NHF's Board of Directors Meeting

The National Hemophilia Foundation will be holding our quarterly Board of Directors meeting on Saturday, October 10th at 9:00 AM EDT.

Hemlibra® is a subcutaneous injection currently indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients ages newborn and older with hemophilia A with or without factor VIII inhibitors.

The Hemophilia Alliance joined with NHF and HFA requesting additional information from Ferring Pharmaceuticals and CSL Behring around the recent Stimate recall.

What are you waiting for? The benefits of mentoring will not only give back to your mentee, but also to your community, and even to you.

New MASAC Recommendations Focus on Offsite Hemostasis Screening and Treatment

A new MASAC document tackles the challenges associated with using off-site laboratories to conduct hemostasis testing for bleeding disorders such as hemophilia and von Willebrand disease.

Study investigators will be looking at how trial participants may develop antibodies against the AAVs that are a key component to Biomarin's gene therapy.

While it’s easy to get wrapped up in checking in on others, it’s important for your mental health to practice self-care.

Recall Notice: Mylan Initiates Voluntary Nationwide Recall of Four Lots of Tranexamic Acid Injection

Tranexamic acid injection is indicated in patients with hemophilia for short term use to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction.

Advisory #428 notes these medications are administered in a hospital setting only by trained healthcare professionals.

Who knew that making a difference in the world could be as easy as wi-fi and your own couch? Leave it to the world of do-gooders to find ways to volunteer, even in the midst of a global pandemic!

The next generation of research starts now

What comes to mind when you think about the future?

NHF Receives Five-Year CDC Grant for Education Programs

The cooperative agreement supports education and awareness programs for bleeding disorders patients, family members, and providers.

When it comes to giving back, there are many ways for you to help out your local nonprofits without having to leave your home.

FDA Recommends Additional Data for BioMarin’s Investigational Gene Therapy

BioMarin plans to meet with the FDA in the coming weeks to align on the next steps to obtain approval.

Concizumab is an investigational therapy designed to be equally effective in individuals with hemophilia A and B, irrespective of inhibitor status

Motivational quotes inspire us to do more, be more and become more of who we are. Each and every one of us can make an impact or difference in this world and leave it better than when we came.

The recall has been expanded from the pharmacy level to the patient, or consumer level.

Ferring has extended the recall of Stimate to the consumer level.

This back-to-school season, do more than simply prepare for a new school year—help those in need.

MASAC Encourages People with Bleeding Disorders to be Included in COVID-19 Vaccine Trials

NHF's Medical and Scientific Advisory Council (MASAC) discussed the role of people with bleeding disorders in SARS-CoV-2 Treatment and Vaccine Trials at NHF's virtual Bleeding Disorders Conference.

New Online Space for Black/African Americans with Bleeding Disorders

The private, online community is for Black and African Americans with bleeding disorders, their family members, and support network.

Stimate Recall Update

CSL Behring and Ferring Pharmaceuticals, Inc have responded to the joint NHF-NHF letter of July 22, 2020, regarding a recent recall of Stimate (desmopressin) nasal spray.

CDC Seeks Perspectives on Living with Chronic Pain

The CDC is looking for 100 participants to discuss using or prescribing different options for pain management.

NHF Increases Financial Support of Chapters

NHF’s new grant program will help chapters during the COVID-19 pandemic.

NHF Opens Nominations for Board of Directors

Board chair Scott Miller calls for more diversity on the board.

Alex Borstein Brings Star Power to Raise Awareness of VWD

NHF and Takeda enlisted the Emmy-award winning actress to feature in a series of PSAs and resources.

A New Path Forward in Research

Leonard Valentino, MD lays groundwork for national research agenda in bleeding disorders.

In 2020, you might be wondering if being happy is something you could admit to—but even during challenging times, there are ways to boost your mood and try to celebrate the good things in life.

NHF’s 72nd Virtual Bleeding Disorders Conference: Provider Education for Physicians, Pharmacists, Nurses, Nurse Practitioners, and Social Workers is jointly provided by Postgraduate Institute for Medicine and the National Hemophilia Foundation.

Our distinguished faculty for this year's syposium will be reviewing the treatments currently available to manage bleeding in these patients and share significant advances being made to improve genetic diagnosis, including valuable insights on how to interpret rare platelet gene panels.

4696 W. Overland Road, Suite 234
Boise, Idaho 83705

© Idaho Chapter of the National Hemophilia Foundaition 2020

Powered by Firespring